What is Brightseed?
Founded in 2017, Brightseed operates at the vanguard of the digital biology revolution. By leveraging advanced machine learning to analyze the dark matter of the plant kingdom, the company identifies hidden health benefits within natural ingredients that were previously unknown to science. This data-driven approach allows Brightseed to partner with global food and wellness enterprises, providing them with actionable insights to develop functional products that support human health. The company's market position is defined by its ability to bridge the gap between complex botanical data and scalable, commercial-ready health solutions, effectively transforming how the industry approaches preventative nutrition and wellness.
How much funding has Brightseed raised?
Brightseed has raised a total of $95M across 2 funding rounds:
Series A
$27M
Series B
$68M
Series A (2020): $27M with participation from CGC Ventures, Seed 2 Growth Ventures, Horizons Ventures, and Lewis & Clark AgriFood Fund II
Series B (2022): $68M led by Temasek
Key Investors in Brightseed
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future. The company seeks to support innovative projects that have the potential to create transformative changes.
Lewis & Clark AgriFood Fund II
Lewis & Clark Partners is a growth equity-focused investment fund specializing in the AgriFood sector, employing a holistic approach that captures value across the entire value chain from pre-production through distribution.
What's next for Brightseed?
With the successful closure of its latest financing round, Brightseed is well-positioned to scale its operational capacity and expand its commercial partnerships. The company intends to utilize this capital to deepen its research into the molecular interactions between plant-based compounds and human biological pathways. As Brightseed transitions from a research-heavy development phase to a broader commercialization strategy, the focus will likely shift toward securing long-term supply chain integrations and regulatory approvals for its novel bioactive ingredients. By maintaining its trajectory of data-driven discovery, Brightseed is poised to become a foundational player in the future of personalized nutrition and health-focused food technology.
See full Brightseed company page
